Trial Profile
A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Dalantercept (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DART
- Sponsors Acceleron Pharma
- 20 May 2021 Protocol of the trial has been amended with change of status ,number of arms, Interventional Study Model and patients number
- 20 May 2021 Status changed from completed to discontinued
- 05 Apr 2019 Part 2 results published in the Cancer